AzTrials
AzTrials

ExerciseNCT04170972

The Role of TBC1D4 in Exercise- and Insulin-induced Glucose Metabolism in Human Skeletal Muscle

A study testing Acute exercise in people with Exercise and Insulin Sensitivity, run by University of Copenhagen at 1 site in Denmark.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Recently a common Greenlandic nonsense p.Arg684erTer variant (in which arginine is replaced by a termination codon) in the gene TBC1D4 was discovered. The variant has an allele frequency of 17%. Read more about this study

Who is it for?
Ages 20 to 70 yearsHealthy volunteers can take part
Conditions the study is for
Exercise, Insulin Sensitivity, Skeletal Muscle
What is being tested?
Acute exercise
Could I receive a placebo?
No, everyone receives an active treatment
How many people
16 participants
Where
1 siteDenmark
Study dates
17 Oct 2017to 1 Sep 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 70 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Homozygote carriers of a pArg684T gene-variant (cases) and matched non carriers (controls)
  • BMI between 20-35 kg/m2

Who cannot join

  • Medical treated type 2 diabetes patients

Trial locations and contacts

1 site in 1 country.

Denmark1 site
  • Department of Exercise, Nutrition and Sports, Faculty of Sciences, University of Copenhagen

    Copenhagen, 2100

Other trials in Denmark

About this study

Recently a common Greenlandic nonsense p.Arg684erTer variant (in which arginine is replaced by a termination codon) in the gene TBC1D4 was discovered. The variant has an allele frequency of 17%. Homozygous carriers of this TBC1D4 variant have impaired glucose tolerance and a 10-fold enhanced risk of developing type 2 diabetes (T2D). The investigators propose to carry out comprehensive metabolic phenotyping of adult Inuits carrying zero or two alleles of the TBC1D4 variant. The investigators hypothesise that regulation of TBC1D4 in skeletal muscle is pivotal in regulating glucose uptake during exercise, during physiological insulin stimulation, and for the ability of an acute bout of exercise to improve insulin sensitivity to regulate glucose metabolism in humans.

The overall aims in the present project are to:

Read more
  1. Determine whether the TBC1D4 p.Arg684Ter variant affects the regulation of glucose uptake in skeletal muscle during exercise and during physiological insulin stimulation.
  2. Determine the effect of the TBC1D4 p.Arg684Ter variant for the ability of acute exercise to insulin sensitize skeletal muscle to regulate glucose metabolism.
  3. Define the metabolic pathways affected by the p.Arg684Ter variant in order to identify causal factors responsible for the diabetic phenotype of Inuit carriers.

The knowledge generated will contribute to additional explanatory clues to the increased frequency of T2D in the carriers.

Read the detailed description

Recently a common Greenlandic nonsense p.Arg684erTer variant (in which arginine is replaced by a termination codon) in the gene TBC1D4 was discovered. The variant has an allele frequency of 17%. Homozygous carriers of this TBC1D4 variant have impaired glucose tolerance and a 10-fold enhanced risk of T2D. The investigators propose to carry out comprehensive metabolic phenotyping of adult Inuits carrying zero or two alleles of the TBC1D4 variant. The investigators hypothesise that regulation of TBC1D4 in skeletal muscle is pivotal in regulating glucose uptake during exercise, during physiological insulin stimulation, and for the ability of an acute bout of exercise to improve insulin sensitivity to regulate glucose metabolism in humans.

Our overall aims in the present project are to:

  1. Determine whether the TBC1D4 p.Arg684Ter variant affects the regulation of glucose uptake in skeletal muscle during exercise and during physiological insulin stimulation.
  2. Determine the effect of the TBC1D4 p.Arg684Ter variant for the ability of acute exercise to insulin sensitize skeletal muscle to regulate glucose metabolism.
  3. Define the metabolic pathways affected by the p.Arg684Ter variant in order to identify causal factors responsible for the diabetic phenotype of Inuit carriers.

The knowledge generated will contribute to additional explanatory clues to the increased frequency of T2D in the carriers.

Study population:

The Inuit Health in Transition (IHIT) study is a study of adults in West and East Greenland. The participants were selected through a stratified random sample and data were collected in 1999-2010 using clinical procedures, sampling of biological material, and questionnaires. To accomplish the goal, the investigators will carry out comprehensive metabolic phenotyping of Inuits carrying zero (n=10) or two (n=10) alleles of the TBC1D4 p.Arg684Ter variant recruited from this cohort. Based on an effect of 1.2 SD as found for plasma glucose levels during an Oral Glucose Tolerance Test (OGTT) in the previous study (6) between homozygous carriers and non-carriers of the TBCD14 variant, the investigators achieve 89% power at p=0.05 when recruiting 10 homozygous carriers and 10 non-carriers.

Methods:

Genotyping of the IHIT cohort has already been performed. Thus, the investigators can re-call study participants for the present study based on their known genotype. The investigators intend to perform highly invasive physiological studies of subjects harboring the TBC1D4 point mutation and in control subjects matched by age, gender and BMI. The participants will be nondiabetic (25-50 yrs) males recruited through the IHIT cohort register (n=4,200). The recruitment, screening and initial clinical investigations (oral glucose tolerance test and physical exercise tests, including customization to a one-legged cycling ergometer) will take place in Greenland. The most invasive part of the study, described below, will take place in Copenhagen, Denmark.

During the stay in Copenhagen participants will receive an energy-matched, standardized diet to be consumed 3 days prior to the intervention study. On the study day the participants will arrive in the laboratory after an overnight fast. Catheters will be placed in both femoral veins (V) and in one femoral artery (A). A muscle biopsy will be obtained from vastus lateralis of one leg (resting leg). The participants will then perform one legged knee extensor exercise for one hour leaving the other leg as a rested control leg. Immediately after exercise a biopsy will be obtained from the exercising leg and the participants will rest in the fasted state for 3 hours before a third set of muscle biopsies (from both legs) and one abdominal subcutaneous fat biopsy are taken. Subsequently, insulin sensitivity will be evaluated during a 2-hour physiological hyperinsulinemic euglycemic clamp. By the end of the clamp a final set of biopsies (both legs) and one abdominal subcutaneous fat biopsy will be obtained. Throughout the study day sampling of artery and venous blood/plasma samples allow estimation of substrate extraction by the two legs. Further, measures of artery blood flow by Ultrasound Doppler technique will allow a final calculation of substrate uptake/release across the two legs before exercise, during exercise and in recovery from exercise. Importantly, the ability for insulin to stimulate theses process can be evaluated in both a rested and in the prior exercised leg.

The investigators plan to carry out deep transcript profiling of muscle tissue samples and define correlations between age, sex, BMI, genetic variants, and the transcriptional profiles in order to understand the impact on gene regulation of identified metabolic genetic variants. In order to define key biochemical pathways affected by the mutated TBC1D4, the investigators will perform metabolomic analyses of the muscle biopsy samples. In order to identify putative targeted pathways affected by the mutation, the investigators will perform mass spectrometry-based interactome as well as proteomic / phosphoproteomic analyses. Based on these data and data obtained from the metabolic analyses, the investigators will be better able to identify the affected metabolic processes involved in the progression towards the diabetic phenotype of the Inuit carriers. Such pathways will in subsequent analyses be studied biochemically in more detail including additional (to phosphorylation) post translational modifications (e.g. glycosylation) as well as expression/activities of key enzymes in glucose and fat metabolism.

Being tested
Acute exercise
Medical subject headings
Motor Activity, Insulin Resistance

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Acute exerciseOther

    Also called Insulin stimulation

    One hour of acute one-legged knee-extensor exercise followed by 3 hours recovery and 2 hours insulin (1.5 mU/min/kg) stimulation.

Study groups in NCT04170972
Study groupRoleWhat they receive
Exercise and vivo insulin stimulation in TBC1D4 gene-variantsExperimentalAcute exercise and in vivo insulin stimulation in homozygote carriers of a p.ARg684T TBC1D4 gene-variant.
Receives: Other: Acute exercise
Exercise and vivo insulin stimulation in matched controlsExperimentalAcute exercise and in vivo stimulation in none carriers (matched controls) of the p.Arg684T TBC1D4 gene-variant.
Receives: Other: Acute exercise

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Changes in leg glucose uptake

    Leg glucose uptake is calculated by the arterial-venous difference i blood glucose concentration multiplied with leg blood flow. Sampling of artery and venous blood samples for blood glucose measurements. Measures of artery blood flow by Ultrasound Doppler technique allows a final calculation of glucose uptake across the legs before exercise, during exercise, in recovery from exercise and with insulin stimulation.

    Measured: Measured 14 times during the experimental day (dispersed over 6 hours)

  2. Changes in whole body insulin sensitivity sensitivity.

    Insulin stimulated glucose uptake at whole body level (glucose infusion rate)

    Measured: 6 times (each 20 minutes) during 2 hours insulin stimulation.

  3. Metabolome.

    Metabolomic analyses to map changes in biochemical pathways in skeletal muscle.

    Measured: At 4 times points: Before exercise, immediately after exercise, 3 hours after exercise and after 2 hours of insulin stimulation.

  4. Transcriptome.

    Transcriptome sequencing in skeletal muscle.

    Measured: At 4 times points: Before exercise, immediately after exercise, 3 hours after exercise and after 2 hours of insulin stimulation.

  5. Changes in the TBC1D4 interactome.

    TBC1D4 interactome analyses, to identify TBC1D4 signaling partners

    Measured: At 4 times points: Before exercise, immediately after exercise, 3 hours after exercise and after 2 hours of insulin stimulation.

  6. Proteome and phosphoproteome.

    Proteomics and targeted phosphoproteomic to identify changes in skeletal muscle.

    Measured: At 4 times points: Before exercise, immediately after exercise, 3 hours after exercise and after 2 hours of insulin stimulation.

  7. Changes in phosphorylation and glycosylation signatures of TBC1D4

    Phosphorylation and glycosylation signatures of the TBC1D4 protein by western blotting to describe regulation of TBC1D4.

    Measured: At 4 times points: Before exercise, immediately after exercise, 3 hours after exercise and after 2 hours of insulin stimulation.

  8. Changes of canonical intermediates in insulin- and exercise-induced signaling

    Expression and/or activity of canonical intermediates in insulin- and exercise-induced signaling and metabolic pathways.

    Measured: At 4 times points: Before exercise, immediately after exercise, 3 hours after exercise and after 2 hours of insulin stimulation.

  9. Changes in leg substrate utilization

    Throughout the study day sampling of artery and venous blood/plasma samples allow estimation of substrate utilization based on the respiratory quotient (RQ).

    Measured: At 4 times points: Before exercise, immediately after exercise, 3 hours after exercise and after 2 hours of insulin stimulation.

Secondary outcomes (2)
  1. Substrate metabolism in primary myotubes from TBC1D4 p.Arg684 variant carriers and controls

    Mechanistic in vitro studies of the TBC1D4 p.Arg684 variant on glucose and fat metabolism.

    Measured: At two conditions: With and without insulin.

  2. Activities of key enzymes in glucose and fat metabolism

    Expression/activities of key enzymes in glucose and fat metabolism in adipose tissue.

    Measured: at 2 time points: Before and after 2 hours of insulin stimulation.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Nov 2019
  2. Study start17 Oct 2017
  3. Primary completion1 May 2019
  4. Study completion1 Sep 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Non-randomised
Intervention model
Parallel groups
Model description
A case-control study with two groups of participants with different genetic background on the TBC1D4 gene: 1. Homozygote carriers of a p.Arg684T TBC1D4 gene-variant 2. None carriers (matched controls) of the p.Arg684T TBC1D4 gene-variant
Masking
None (open label)
Enrolment
16 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04170972
Sponsor's protocol ID
KVUG 2016-12
Other IDs
H-18007316, 13057, 5053-00095B, 28136
Status last verified
Apr 2021
First submitted
23 Apr 2019
Last updated
6 Jan 2022
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Moltke I, Grarup N, Jorgensen ME, Bjerregaard P, Treebak JT, Fumagalli M, Korneliussen TS, Andersen MA, Nielsen TS, Krarup NT, Gjesing AP, Zierath JR, Linneberg A, Wu X, Sun G, Jin X, Al-Aama J, Wang J, Borch-Johnsen K, Pedersen O, Nielsen R, Albrechtsen A, Hansen T. A common Greenlandic TBC1D4 variant confers muscle insulin resistance and type 2 diabetes. Nature. 2014 Aug 14;512(7513):190-3. doi: 10.1038/nature13425. Epub 2014 Jun 18.

    PubMed 25043022

Questions about this trial

What is this clinical trial studying?

A study testing Acute exercise in people with Exercise and Insulin Sensitivity, run by University of Copenhagen at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 Jan 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Changes in leg glucose uptake (time frame: Measured 14 times during the experimental day (dispersed over 6 hours)). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04170972, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jan 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in